Peer Exchange


Management of Cardiac Amyloidosis

Key opinion leaders consider the diagnostic workup for differentiating patients referred with general amyloidosis.

A discussion on the historical prognosis of hypertrophic cardiomyopathy with conventional management.

A discussion on the subtle diagnosis of immunoglobulin light chain amyloidosis and transthyretin amyloidosis, with consideration for echocardiogram features and noncardiac biopsy.

Experts in the field of cardiac amyloidosis management discuss when heart biopsies are necessary and consider possible adverse events.

The benefits of using technetium pyrophosphate scans to diagnose cardiac amyloidosis and the prevalence of transthyretin amyloidosis.

The importance of lab testing for monoclonal proteins to interpret the results of technetium pyrophosphate scans and the significance of wild-type transthyretin amyloidosis. 
SAP Partner Banner